Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Sciences, Inc.

http://www.gilead.com

Latest From Gilead Sciences, Inc.

The Value And Challenge Of Focus In Pharma

A 10-year review of the top 20 biopharmaceutical companies by revenue found that portfolio focus, not therapeutic area diversity, delivered the strongest growth rates.

Business Strategies Commercial

COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says

Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."

Coronavirus COVID-19 Leadership

US FDA's Ebola Drug Approvals Showcase Efficiencies With Master Protocols

Agency approved Regeneron’s monoclonal antibody cocktail Inmazeb and Ridgeback’s mAB Ebanga on data from a multi-arm, adaptive trial in which several investigational agents were independently compared to a control group. Efficacy for both drugs was demonstrated on a mortality endpoint, with lingering uncertainties to be addressed through postmarketing studies.

Drug Review Profile Approvals

Inmazeb Brought Regeneron A Priority Review Voucher, But Not The Type It Wanted

Sponsor preferred a tropical disease voucher because it could be redeemed for a supplemental application, but the FDA awarded a voucher under the medical countermeasures program, which prohibits redemption for supplements; agency says it takes a case-by-case approach to deciding whether tropical disease and rare pediatric disease vouchers can be redeemed for supplements.

Drug Review Profile Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Arresto Biosciences, Inc.
    • Asegua Therapeutics, LLC
    • Calistoga Pharmaceuticals, Inc.
    • CGI Pharmaceuticals, Inc.
    • CV Therapeutics, Inc.
    • Cytopia Limited
    • EpiTherapeutics
    • Eximias Pharmaceutical Corporation
    • Immunomedics, Inc.
    • Myogen
    • Nimbus Apollo, Inc.
    • Nexstar Pharmaceuticals
    • Oligogen, Inc.
    • Pharmasset, Inc.
    • Triangle Pharmaceuticals
    • YM BioSciences Inc. (YMI)
    • Kite Pharma, Inc.
    • Kite Pharma EU
    • T-Cell Factory B.V. (TCF)
    • Cell Design Labs, Inc.
    • Asegua Therapeutics
UsernamePublicRestriction

Register